Can only loosely begin to understand appreciate your frustration over the years and don't disagree most of your points. Alas the ASX rife with listed company boards that do little but go through their governance required motions. But Killian is surely an reasonable transition CEO for ousted Ross and his experience and knowledge of the company is at least thorough? Surely a far better option than continuing with a CEO that couldn't get an agreement with a Sumitomo $2 buy-out, that then stewarded the company through a share price decline to a low of 5% of that price ($0.10) in 4 years? You rightly mention big Pharma can pick this up for peanuts.
Almost 4 years almost to the day! It must be massively frustrating for you as an long-term investor. I genuinely hope for your sake you took at least a few profits off the table near the highs:
CYP is a ridiculously more arguable value buy for someone like Sumitomo down here and its prospects with NHMRC and LUMC funded trials surely offset the Fujifilm business misadventures shall we call them? The poorly timed and executed capital raise and recent wider macro-financial conditions aside, CYP is a bit ridiculous at a $24 million cap.
CYP Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)